Affy Caps off a Remarkable Rebound in 2001: Will New Affability Lead to Profitability? | GenomeWeb

For Affymetrix, the settlement with Incyte caps off what has been been a remarkable comeback in the second half of 2001.

“This has been an incredible year for Affymetrix,” said company spokesperson Anne Bowdidge. “It has been an challenging year as well.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.